Cargando…

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples

Objective. A proportion of RA and SLE patients treated with standard doses of rituximab (RTX) display inefficient B cell deletion and poor clinical responses that can be augmented by delivering higher doses, indicating that standard-dose RTX is a sub-optimal therapy in these patients. This study aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reddy, Venkat, Klein, Christian, Isenberg, David A., Glennie, Martin J., Cambridge, Geraldine, Cragg, Mark S., Leandro, Maria J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Basic and Translational Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808665/ https://www.ncbi.nlm.nih.gov/pubmed/28407142 http://dx.doi.org/10.1093/rheumatology/kex067

Ejemplares similares

Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus
por: Reddy, Venkat, et al.
Publicado: (2015)

Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?
por: Reddy, Venkat R, et al.
Publicado: (2021)

Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long‐Term Effects on Serum Immunoglobulins
por: Reddy, Venkat, et al.
Publicado: (2017)

Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis
por: Hennessey, Ashleigh, et al.
Publicado: (2019)

Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis
por: Leonard, Dag, et al.
Publicado: (2018)

Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020
por: Norris-Grey, Caitlin, et al.
Publicado: (2021)

Autophagy is activated in systemic lupus erythematosus and required for plasmablast development
por: Clarke, Alexander J, et al.
Publicado: (2015)

Monocyte Siglec-14 expression is upregulated in patients with systemic lupus erythematosus and correlates with lupus disease activity
por: Thornhill, Susannah I., et al.
Publicado: (2017)

DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus
por: Imgenberg-Kreuz, Juliana, et al.
Publicado: (2018)

Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis
por: Lyons, Paul A, et al.
Publicado: (2010)

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
por: Alexander, Tobias, et al.
Publicado: (2015)

Follow up study of B-lymphocyte depletion in the treatment of patients with systemic lupus erythematosus
por: Leandro, MJ, et al.
Publicado: (2005)

Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations
por: Gilaberte Reyzabal, Sergio, et al.
Publicado: (2022)

Proportions of B-cell subsets are altered in incomplete systemic lupus erythematosus and correlate with interferon score and IgG levels
por: Henning, Svenja, et al.
Publicado: (2020)

Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus
por: Schafer, Peter H, et al.
Publicado: (2018)

Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus – report of 17 cases and review of the literature
por: Hofmann, SC, et al.
Publicado: (2013)

Apoptosis-derived membrane vesicles drive the cGAS–STING pathway and enhance type I IFN production in systemic lupus erythematosus
por: Kato, Yasuhiro, et al.
Publicado: (2018)

Obinutuzumab Rescue in Rituximab Resistant Mixed Cryoglobulinemia
por: Genest, Dominique S., et al.
Publicado: (2021)

Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways
por: Edelmann, Jennifer, et al.
Publicado: (2021)

Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-G
por: Fernando, Michelle M A, et al.
Publicado: (2012)

Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus
por: Wincup, Chris, et al.
Publicado: (2022)

GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race
por: García-Muñoz, Ricardo, et al.
Publicado: (2019)

Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report
por: Lachowiez, Curtis, et al.
Publicado: (2017)

Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus
por: Wincup, Chris, et al.
Publicado: (2019)

Off-label use of rituximab for systemic lupus erythematosus in Europe
por: Rydén-Aulin, Monica, et al.
Publicado: (2016)

Serum Midkine Levels in Systemic Lupus Erythematosus
por: Marpaung, Blondina, et al.
Publicado: (2018)

The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness
por: Gracia-Tello, Borja, et al.
Publicado: (2017)

Use of rituximab, temozolomide, and radiation in recurrent and refractory primary central nervous system lymphoma in the Philippines: a retrospective analysis
por: Batara, Julette Marie F, et al.
Publicado: (2022)

Mixed Cryoglobulinaemia Vasculitis Treated with Obinutuzumab in a Patient Allergic to Rituximab
por: Gaudêncio, Margarida, et al.
Publicado: (2021)

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
por: Albertsson-Lindblad, Alexandra, et al.
Publicado: (2019)

2114 Severity of childhood-onset systemic lupus erythematosus: Impact of preceding and co-existing autoimmune cytopenias (protocol)
por: Akan, Ekemini, et al.
Publicado: (2018)

2456 Cutaneous lupus erythematosus patients have increased circulating myeloid-derived suppressor cells with immunosuppressive properties
por: Florez-Pollack, Stephanie, et al.
Publicado: (2018)

MICL controls inflammation in rheumatoid arthritis
por: Redelinghuys, Pierre, et al.
Publicado: (2016)

Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab
por: Agez, Morgane, et al.
Publicado: (2019)

Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model
por: Decaup, E, et al.
Publicado: (2013)

Rituximab therapy for juvenile-onset systemic lupus erythematosus
por: Nwobi, Obioma, et al.
Publicado: (2007)

Rituximab reduces the hospitalization in patients with systemic lupus erythematosus
por: Martínez-Pérez, R, et al.
Publicado: (2010)

Akaluc bioluminescence offers superior sensitivity to track in vivo glioma expansion
por: Bozec, Dominique, et al.
Publicado: (2020)

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis
por: Vallerskog, Therese, et al.
Publicado: (2006)

Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis
por: Bell, G M, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5fnqrph4vt4s6dnb1qmrub9slk